Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chang Jiang Pharma to Supply Biodel with API for Insulin Aspart

publication date: Apr 25, 2014
Yichang Chang Jiang Pharma will supply Biodel of the US with research supplies of the API for insulin aspart, the API in Novolog®, a Novo Nordisk fast-acting insulin. Biodel intends to reformulate the drug into an ultra-fast version. As part of the agreement, Biodel has granted Chang Jiang’s parent, HEC Pharm, an option to negotiate for China rights to any resulting product candidates. More details....

Stock Symbol: (NSDQ: BIOD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital